Dana Washburn has been appointed chief medical officer of Lyra Therapeutics. Washburn comes to Watertown, MA-based Lyra from Parexel, where he was corporate vice president and head of global medical services. Lyra develops treatments for ear, nose, and throat diseases. Last year, the company closed $29.5 million in Series B financing to support mid-stage tests of LYR-210, an experimental treatment for the long-term sinus inflammation called chronic rhinosinusitis.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
